Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
Medical Device

Siemens distributes Nucletron's Oncentra MasterPlan oncology software:

This article was originally published in Clinica

  • News

Executive Summary

Dutch cancer treatment products developer Nucletron has signed up German multinational Siemens Medical Solutions as non-exclusive, worldwide distributor of its Oncentra MasterPlan software solution. The product consists of four individual treatment-planning modules for external-beam radiotherapy: Oncentra Anatomy is used for contouring, segmentation, and multi-modality image registration and fusion; Oncentra virtual Simulation provides image manipulation and advanced contouring tools, easy beam set-up and real-time generated detailed design reports; Oncentra Optimizer gives users rapid optimisation through an advanced algorithm; and Oncentra Evaluation allows interactive dose shaping for 3D plan evaluation and generates dose volume histograms.

Table

View full table

Topics

Tags:
Medical Device
Latest Headlines

Valuable Health Data Sources For Medtech Industry Come A Step Closer In The EU

Rise In Class I Device Recalls A ‘Grave Concern,’ Says FDA’s Anne Reid

Discreet Gait Freezing Solution Brings Therapy With The Tap Of An Apple Watch

Shuren Says CDRH Is ‘Turning The Ship Around’ As Operations Return To Normal

See All
UsernamePublicRestriction

Register

MT058035

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By